podcasts
Advanced techniques in toxicity testing
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
List view / Grid view
Cell-based assays
article
Finding the right CDMO partner for cell line development
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. However, the creation of cell lines is a technically demanding and time-consuming process. For this reason, many businesses seek partnerships with contract development and manufacturing…
article
Driving efficiency across upstream bioprocess workflow
Dr Anis H Khimani from Revvity explores how key developments have enhanced biotherapeutic workflows, and explores how a transposon system can aid stable clone development.
webinar
Advancing therapeutics targeting cytokines with functional cell-based assays
3 January 2024 | By Eurofins DiscoverX
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
podcasts
Episode 24 – Genetic engineering for allogeneic immunotherapy
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
article
Huntington’s disease and potential therapies
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
webinar
Functional assays for the development of agonistic antibodies
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
article
The promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
article
Next-generation CAR T cells
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
article
Women in STEM with Dr Jo Brewer
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been…
article
Game-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
article
Neoantigen-directed cancer treatment
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
article
ebook: Advances In Cell Imaging and Retrieval
Unleash the power of drug discovery with this FREE ebook supported by Sartorius! Explore the limitless potential of CRISPR applications and single cell sequencing for drug discovery. Access exclusive insights from industry leaders and stay ahead of the curve with the latest trends. Don't miss out on this opportunity to…
webinar
Validated bioassays for metabolic & gastrointestinal diseases: Accelerating development of GLP-1 & -2 therapeutics
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.